Theodore Louis Dern, MD | |
2001 Errecart Blvd, Elko, NV 89801-8333 | |
(775) 938-5151 | |
Not Available |
Full Name | Theodore Louis Dern |
---|---|
Gender | Male |
Speciality | Radiology - Diagnostic Radiology |
Location | 2001 Errecart Blvd, Elko, Nevada |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1235238262 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
2085R0202X | Radiology - Diagnostic Radiology | 8646 (Nevada) | Primary |
Mailing Address | Practice Location Address |
---|---|
Theodore Louis Dern, MD 605 Wolf Creek Dr, Spring Creek, NV 89815-7240 Ph: (775) 753-6714 | Theodore Louis Dern, MD 2001 Errecart Blvd, Elko, NV 89801-8333 Ph: (775) 938-5151 |
News Archive
As planners race to finish building the online marketplaces that consumers can begin using Oct. 1 to shop for health insurance, experts expect some difficulties, according to The Wall Street Journal. Meanwhile, CQ HealthBeat examines whether the deductibles and out-of-pocket caps applied in these marketplaces will be too high.
Warren K. Bickel, director of the Center for Substance Abuse at the Virginia Tech Carilion Research Institute, has been selected as the 2011 recipient of the American Psychological Association Don Hake Translational Research Award. Sponsored by the Association for Behavior Analysis International, the award recognizes individuals whose work spans basic and applied research.
A team of cardiologists, materials scientists, and bioengineers have created and tested a new type of implantable device for measuring the heart's electrical output that they say is a vast improvement over current devices. The new device represents the first use of flexible silicon technology for a medical application.
Follow-Up Study Published in the Journal of Parkinson's Disease Supports an Earlier "Proof of Concept" Trial. A follow-up study of patients with Parkinson's disease (PD) who participated in an earlier "proof of concept" clinical trial using exenatide showed that improvements persisted twelve months after discontinuing exenatide therapy.
Aid groups in West Africa are trying out new strategies and products for treating moderate acute malnutrition (MAM) as part of a U.N.-led effort to change 30 year old policies, IRIN reports.
› Verified 4 days ago